Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 19 studies | 43% ± 20% | |
peripheral blood | 18 studies | 32% ± 9% | |
lung | 17 studies | 33% ± 13% | |
eye | 11 studies | 48% ± 15% | |
intestine | 10 studies | 25% ± 14% | |
kidney | 8 studies | 32% ± 6% | |
liver | 6 studies | 31% ± 14% | |
heart | 5 studies | 23% ± 2% | |
pancreas | 4 studies | 62% ± 19% | |
placenta | 4 studies | 24% ± 7% | |
bone marrow | 4 studies | 23% ± 5% | |
uterus | 4 studies | 30% ± 13% | |
prostate | 4 studies | 26% ± 7% | |
lymph node | 4 studies | 36% ± 13% | |
breast | 4 studies | 29% ± 3% | |
adipose | 4 studies | 29% ± 7% | |
adrenal gland | 3 studies | 24% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 9256.95 | 258 / 258 | 100% | 186.62 | 230 / 230 |
esophagus | 100% | 5162.12 | 1445 / 1445 | 100% | 60.24 | 183 / 183 |
liver | 100% | 6407.59 | 226 / 226 | 100% | 86.87 | 406 / 406 |
ovary | 100% | 7293.58 | 180 / 180 | 100% | 92.80 | 430 / 430 |
pancreas | 100% | 4470.49 | 328 / 328 | 100% | 82.16 | 178 / 178 |
prostate | 100% | 6695.03 | 245 / 245 | 100% | 126.32 | 502 / 502 |
thymus | 100% | 13393.39 | 653 / 653 | 100% | 168.75 | 605 / 605 |
brain | 100% | 14996.84 | 2640 / 2642 | 100% | 199.10 | 705 / 705 |
lung | 100% | 7048.29 | 577 / 578 | 100% | 68.03 | 1155 / 1155 |
breast | 100% | 7404.88 | 459 / 459 | 100% | 106.47 | 1116 / 1118 |
uterus | 100% | 6795.16 | 170 / 170 | 100% | 61.35 | 458 / 459 |
kidney | 100% | 7599.99 | 89 / 89 | 100% | 98.58 | 898 / 901 |
stomach | 100% | 5333.90 | 359 / 359 | 100% | 66.87 | 285 / 286 |
bladder | 100% | 7248.95 | 21 / 21 | 99% | 61.33 | 501 / 504 |
intestine | 100% | 5560.80 | 966 / 966 | 99% | 64.92 | 523 / 527 |
skin | 100% | 5467.50 | 1805 / 1809 | 97% | 65.97 | 457 / 472 |
adipose | 100% | 7656.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10572.66 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 6207.01 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 47.08 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.38 | 1 / 1 |
muscle | 99% | 3724.55 | 791 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 5193.30 | 814 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 39.78 | 27 / 29 |
eye | 0% | 0 | 0 / 0 | 91% | 47.37 | 73 / 80 |
peripheral blood | 63% | 1984.21 | 583 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051224 | Biological process | negative regulation of protein transport |
GO_0032410 | Biological process | negative regulation of transporter activity |
GO_0002761 | Biological process | regulation of myeloid leukocyte differentiation |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0035739 | Biological process | CD4-positive, alpha-beta T cell proliferation |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0030001 | Biological process | metal ion transport |
GO_0002829 | Biological process | negative regulation of type 2 immune response |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0006879 | Biological process | intracellular iron ion homeostasis |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0032713 | Biological process | negative regulation of interleukin-4 production |
GO_0045619 | Biological process | regulation of lymphocyte differentiation |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0007034 | Biological process | vacuolar transport |
GO_0048294 | Biological process | negative regulation of isotype switching to IgE isotypes |
GO_0048302 | Biological process | regulation of isotype switching to IgG isotypes |
GO_2000562 | Biological process | negative regulation of CD4-positive, alpha-beta T cell proliferation |
GO_0005576 | Cellular component | extracellular region |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0030425 | Cellular component | dendrite |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0045202 | Cellular component | synapse |
GO_0005938 | Cellular component | cell cortex |
GO_0010008 | Cellular component | endosome membrane |
GO_0050699 | Molecular function | WW domain binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NDFIP1 |
Protein name | NEDD4 family-interacting protein 1 (Breast cancer-associated protein SGA-1M) (NEDD4 WW domain-binding protein 5) (Putative MAPK-activating protein PM13) (Putative NF-kappa-B-activating protein 164) (Putative NFKB and MAPK-activating protein) |
Synonyms | N4WBP5 PSEC0192 PSEC0223 |
Description | FUNCTION: Activates HECT domain-containing E3 ubiquitin-protein ligases, including NEDD4 and ITCH, and consequently modulates the stability of their targets. As a result, controls many cellular processes. Prevents chronic T-helper cell-mediated inflammation by activating ITCH and thus controlling JUNB degradation (By similarity). Promotes pancreatic beta cell death through degradation of JUNB and inhibition of the unfolded protein response, leading to reduction of insulin secretion . Restricts the production of pro-inflammatory cytokines in effector Th17 T-cells by promoting ITCH-mediated ubiquitination and degradation of RORC (By similarity). Together with NDFIP2, limits the cytokine signaling and expansion of effector Th2 T-cells by promoting degradation of JAK1, probably by ITCH- and NEDD4L-mediated ubiquitination (By similarity). Regulates peripheral T-cell tolerance to self and foreign antigens, forcing the exit of naive CD4+ T-cells from the cell cycle before they become effector T-cells (By similarity). Negatively regulates RLR-mediated antiviral response by promoting SMURF1-mediated ubiquitination and subsequent degradation of MAVS . Negatively regulates KCNH2 potassium channel activity by decreasing its cell-surface expression and interfering with channel maturation through recruitment of NEDD4L to the Golgi apparatus where it mediates KCNH2 degradation . In cortical neurons, mediates the ubiquitination of the divalent metal transporter SLC11A2/DMT1 by NEDD4L, leading to its down-regulation and protection of the cells from cobalt and iron toxicity . Important for normal development of dendrites and dendritic spines in cortex (By similarity). Enhances the ubiquitination of BRAT1 mediated by: NEDD4, NEDD4L and ITCH and is required for the nuclear localization of ubiquitinated BRAT1 . Enhances the ITCH-mediated ubiquitination of MAP3K7 by recruiting E2 ubiquitin-conjugating enzyme UBE2L3 to ITCH (By similarity). Modulates EGFR signaling through multiple pathways. In particular, may regulate the ratio of AKT1-to-MAPK8 signaling in response to EGF, acting on AKT1 probably through PTEN destabilization and on MAPK8 through ITCH-dependent MAP2K4 inactivation. As a result, may control cell growth rate . Inhibits cell proliferation by promoting PTEN nuclear localization and changing its signaling specificity . . |
Accessions | ENST00000253814.6 [Q9BT67-1] Q9BT67 |